Oncoquest-Ovarian Cancer (ovarian cancer vaccine) / R2T Biopharma - LARVOL DELTA

[VIRTUAL] Final survival follow-up and translational associations using interval indirect immunization with oregovomab (O) and poly ICLC in patients (pts) with recurrent platinum-resistant ovarian cancer (PROC). (ASCO 2021) - P1, P3 | "Funding: OncoQuest Pharma USA, Inc., DE Clinical Trial Registry Number: NCT03162562 Background: Indirect immunization with tumor specific antibody is an approach to triggering therapeutic immunity to cancer through activated immune cells...Interval administration of second-line Rx (bevacizumab, paclitaxel, carboplatin, &/or doxorubicin) and O were associated with further antibody spikes... H is a viable immune adjuvant for combination with O suitable for further study in immune resistant settings . Immune responsiveness was similar to that observed in a prior study of same day schedule of carboplatin-paclitaxel front-line immunotherapy (Braly, JIT 2009; Battaglia, Cll, 2020) . Patterns of immune response to O in the setting of recurrent ovarian cancer are influenced by concomitant anti-neoplastic therapy ."

Clinical • Oncology • Ovarian Cancer • Solid Tumor • MUC16